CYP2C9

From Wikipedia, the free encyclopedia

You have new messages (last change).

Cytochrome P450 2C9 (abbreviated CYP2C9), a member of the cytochrome P450 mixed-function oxidase system, is involved in the metabolism of xenobiotics in the body. It is involved in the metabolism of several important groups of drugs including many non-steroidal anti-inflammatory drugs (NSAIDs) and sulfonylureas.

Genetic polymorphism exists for CYP2C9 expression, with approximately 1–3% of Caucasian populations being poor metabolisers with no CYP2C9 function.

[edit] CYP2C9 Ligands

Selected inducers, inhibitors and substrates of CYP2C91
Type Agent
inducers rifampicin, secobarbital, hyperforin (constituent of St Johns Wort)
inhibitors amiodarone, fenofibrate, fluconazole, fluvastatin, fluvoxamine, isoniazid, lovastatin, probenecid, sertraline, sulfamethoxazole, teniposide, voriconazole, zafirlukast
substrates amitriptyline, certain angiotensin II receptor antagonists (losartan, irbesartan), fluoxetine, fluvastatin, NSAIDs (incl. celecoxib, diclofenac, ibuprofen, meloxicam, naproxen, piroxicam), pitavastatin, phenytoin, rosiglitazone, sulfonylureas (incl. glibenclamide, glipizide, glimepiride, tolbutamide), tamoxifen, warfarin
Notes:
  1. Where classes of agents are listed, there may be exceptions within the class.

[edit] See also

Retrieved from "http://en.wikipedia.org../../../c/y/p/CYP2C9_3ba0.html"